ArticleACS nanoscience Au2025
Berberine's Impact on Apoptosis, Proliferation, Uptake Efficiency, and Nanoparticle-Based Therapy in DBTRG Cells.
Article in ACS nanoscience Au, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Room-Temperature Synthesis of Anionic Covalent Organic Framework Monolithic Materials for Efficient Capturing of Berberine Hydrochloride.Journal of separation science · 2026Article
- Interface Wettability Transition-Driven Drug Release and Dual-Phase Functionalization in Implant Abutment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The Redox Paradox of Natural Supplements in Cancer: A Narrative Review to Guide Clinical Practice.Antioxidants (Basel, Switzerland) · 2026Review
- Berberine as a Multifunctional Adjuvant in Cancer Therapy: Mechanistic Insights, Nanotechnological Strategies, and Translational Challenges.Pharmaceuticals (Basel, Switzerland) · 2026Review
- From Polyphenols to Prodrugs: Bridging the Blood-Brain Barrier with Nanomedicine and Neurotherapeutics.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study examined the effects of berberine, a bioactive alkaloid, on the apoptosis, proliferation, migration, and oxidative stress of DBTRG brain cancer cells and evaluated its potential when incorporated into a nanoparticle-mediated drug delivery system. DBTRG cells treated with 0.5, 1, 5, or 10 μg/mL of berberine for 48 h showed increased apoptosis through both intrinsic and extrinsic pathways, as evidenced by elevated annexin V+/propidium iodide- cells relative to untreated controls. Berberine effectively reduced cell proliferation by inducing cell cycle arrest at G1 and G2/M phases. It also inhibited cell migration by downregulating matrix metalloproteinases and modifying the cytoskeletal structure, and alleviated oxidative stress by enhancing antioxidant enzyme activity and lowering reactive oxygen species production. To overcome the limitations of berberine's low bioavailability, a nanoparticle-based delivery system was developed. The gold-collagen-berberine (Au-Col-BB) nanocarrier was characterized using UV-vis spectrophotometry, Fourier-transform infrared spectroscopy, dynamic light scattering, energy-dispersive X-ray spectroscopy, X-ray photoelectron spectroscopy, and scanning electron microscopy. Au-Col-BB nanoparticles were engineered to enhance berberine's loading capacity and therapeutic efficacy. These nanoparticles entered DBTRG cells via endocytosis and progressed through the endosome-lysosome pathway, which significantly increased cellular uptake and therapeutic effectiveness. Annexin V/propidium iodide staining and cell cycle analysis demonstrated that Au-Col-BB nanoparticles promoted DBTRG cell apoptosis. The sub-G1 phase cell population increased by 19.4% (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.